Active immunization trial in Aβ42-injected P301L tau transgenic mice

被引:18
作者
Kulic, L
Kurosinski, P
Chen, F
Tracy, J
Mohajeri, MH
Li, H
Nitsch, RM
Götz, J
机构
[1] Univ Sydney, Brain & Mind Res Inst, Camperdown, NSW 2050, Australia
[2] Univ Zurich, Div Psychiat Res, CH-8008 Zurich, Switzerland
关键词
Alzheimer's disease; brain; vaccination; amyloid beta-peptide; tau; transgenic; neurofibrillary tangles;
D O I
10.1016/j.nbd.2005.10.002
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Amyloid beta-peptide (A beta) containing plaques and neurofibrillary tangles (NFT) are the two major histopathological hallmarks of Alzheimer's disease (AD). According to the amyloid cascade hypothesis, deposition of A is an initial and essential step in the pathogenesis of AD, and formation of NFT has been proposed to be caused by increased A beta levels. Several previous studies revealed that A beta plaque formation can be reduced or even prevented by active immunization with A beta preparations or by administration of A beta-specific antibodies. To assess the role of fibrillar preparations of A beta(42) in NFT formation, we previously performed intracerebral (i.c.) injections of A beta(42) into brains of NFT-forming P301L tau transgenic mice which caused significant increases in NFT numbers. To determine whether these increases in NFT can be blocked or reduced by active immunization, P301L tau mice were immunized with intraperitoneal injections of preaggregated A beta(42). A beta(42)-specific titers were monitored and the mice injected i.c. with A beta(42). We found that i.c. injection of A beta(42) caused significant increases in NFT formation. However, this induction was not affected by active immunization despite high serum anti-A beta(42) titer levels and binding of anti-A beta(42) antibodies to the injected A beta(42) aggregates. We conclude that active immunization is not sufficient to prevent the effect of A beta(42) On tau aggregation in our model system. Further studies are required to determine whether modifications of our protocol could affect the A beta(42)-mediated induction of NFT formation. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:50 / 56
页数:7
相关论文
共 50 条
  • [31] Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1α, and phosphorylates GSK3β in P301L tau transgenic mice
    Fine, J. M.
    Baillargeon, A. M.
    Renner, D. B.
    Hoerster, N. S.
    Tokarev, J.
    Colton, S.
    Pelleg, A.
    Andrews, A.
    Sparley, K. A.
    Krogh, K. M.
    Frey, W. H.
    Hanson, L. R.
    EXPERIMENTAL BRAIN RESEARCH, 2012, 219 (03) : 381 - 390
  • [32] Tau Passive Immunotherapy in Mutant P301L Mice: Antibody Affinity versus Specificity
    d'Abramo, Cristina
    Acker, Christopher M.
    Jimenez, Heidy T.
    Davies, Peter
    PLOS ONE, 2013, 8 (04):
  • [33] Reduced number of axonal mitochondria and tau hypophosphorylation in mouse P301L tau knockin neurons
    Rodriguez-Martin, Teresa
    Pooler, Amy M.
    Lau, Dawn H. W.
    Morotz, Gabor M.
    De Vos, Kurt J.
    Gilley, Jonathan
    Coleman, Michael P.
    Hanger, Diane P.
    NEUROBIOLOGY OF DISEASE, 2016, 85 : 1 - 10
  • [34] Dietary Cholesterol and Its Effect on Tau Protein: A Study in Apolipoprotein E-Deficient and P301L Human Tau Mice
    Gloeckner, Frauke
    Meske, Volker
    Luetjohann, Dieter
    Ohm, Thomas G.
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2011, 70 (04) : 292 - 301
  • [35] Tau pathology in a family with dementia and a P301L mutation in tau
    Mirra, SS
    Murrell, JR
    Gearing, M
    Spillantini, MG
    Goedert, M
    Crowther, A
    Levey, AI
    Jones, R
    Green, J
    Shoffner, JM
    Wainer, BH
    Schmidt, ML
    Trojanowski, JQ
    Ghetti, B
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1999, 58 (04) : 335 - 345
  • [36] Developmental Pathogenicity of 4-Repeat Human Tau Is Lost with the P301L Mutation in Genetically Matched Tau-Transgenic Mice
    Gamache, Julia E.
    Kemper, Lisa
    Steuer, Elizabeth
    Leinonen-Wright, Kailee
    Choquette, Jessica M.
    Hlynialuk, Chris
    Benzow, Kellie
    Vossel, Keith A.
    Xia, Weiming
    Koob, Michael D.
    Ashe, Karen H.
    JOURNAL OF NEUROSCIENCE, 2020, 40 (01) : 220 - 236
  • [37] A family with a tau P301L mutation presenting with parkinsonism
    Walker, RH
    Friedman, J
    Wiener, J
    Hobler, R
    Gwinn-Hardy, K
    Adam, A
    DeWolfe, J
    Gibbs, R
    Baker, M
    Farrer, M
    Hutton, M
    Hardy, J
    PARKINSONISM & RELATED DISORDERS, 2002, 9 (02) : 121 - 123
  • [38] Effect size of memory deficits in mice with adult-onset P301L tau expression
    Hunsberger, Holly C.
    Rudy, Carolyn C.
    Weitzner, Daniel S.
    Zhang, Chong
    Tosto, David E.
    Knowlan, Kevin
    Xu, Ying
    Reed, Miranda N.
    BEHAVIOURAL BRAIN RESEARCH, 2014, 272 : 181 - 195
  • [39] The impact of pimavanserin on psychotic phenotypes and tau phosphorylation in the P301L/COMT- and rTg(P301L)4510 mouse models of Alzheimer's disease
    Jimenez, Heidy
    Adrien, Leslie
    Wolin, Adam
    Eun, John
    Chang, Eric H. H.
    Burstein, Ethan S. S.
    Gomar, Jesus
    Davies, Peter
    Koppel, Jeremy
    ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2022, 8 (01)
  • [40] Familial Semantic Dementia with P301L Mutation in the Tau Gene
    Ishizuka, Takanori
    Nakamura, Masayuki
    Ichiba, Mio
    Sano, Akira
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2011, 31 (05) : 334 - 340